Aside from Murdoch new indications (which wont do much) I think first patient dosed would. Covid positive results might. Third quarter dystrophin results would but that's too far away. Financing the remaining 16m would but perhaps we're pushing as far ahead without it. which brings me back to first patient dosed.
or,
Takeover offer at $5B
For General Information, page-42
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.9¢ | $51.87K | 520.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 271752 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 206056 | 3 |
View Market Depth
| Last trade - 14.59pm 25/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |